Antivirals against SARS-CoV2: Relevance to the treatment of Alzheimer's disease. - GreenMedInfo Summary
Antivirals Against SARS-CoV2: Relevance to the Treatment of Alzheimer's Disease.
J Alzheimers Dis. 2020 Oct 13. Epub 2020 Oct 13. PMID: 33074241
Ruth F Itzhaki
A recent study in vitro has shown that a sulphated polysaccharide, a type of fucoidan, has potent antiviral activity against SARS-Cov2. If the antiviral action were successful also for COVID-19 patients, it would be enormously valuable against not only acute disease but also long-term mental effects, which might include Alzheimer's disease (AD). In a trial of AD patients, the apparent success of treatment with a polysaccharide, GV971, was suggested to result from antiviral action against herpes simplex virus type 1 (HSV1) in brain, a pathogen strongly implicated in AD, and that sulphation of GV971, making it fucoidan-like, might increase its putative antiviral action. These data indicate that treatment of AD patients might be very effective using valacyclovir, a conventional antiviral, which inhibits viral replication, together with a fucoidan, which blocks virus entry into cells.